Accelerated Cure Project for Multiple Sclerosis and Arab Board for Clinical Research Partner with the Association of Diversity in Clinical Trials

News
Article
Image Credit: © BillionPhotos.com - stock.adobe.com

Image Credit: © BillionPhotos.com - stock.adobe.com

The Association of Diversity in Clinical Trials (AOD) has announced its newest partners, Accelerated Cure Project for Multiple Sclerosis and Arab Board for Clinical Research. This strategic collaboration aims to drive diversity and inclusion within the realm of clinical trials, addressing longstanding disparities in healthcare access.

AOD, an advocate for diversity and equity in clinical research, has forged these partnerships to expand its impact on underrepresented populations. Accelerated Cure Project for Multiple Sclerosis, a nonprofit organization dedicated to advancing multiple sclerosis (MS) research, shares AOD's commitment to equal access to treatments and therapies for all patients, regardless of their background. The Arab Board for Clinical Research, renowned for its advocacy work in the clinical research space, joins forces with AOD to enhance diversity in clinical trials on a global scale.

"Our partnership with the Accelerated Cure Project for Multiple Sclerosis and the Arab Board for Clinical Research is a vital step in addressing clinical trial disparities," stated Jeremy Mitchell, AOD's director of business development in a press release. "Together, we aim to improve healthcare outcomes for all by ensuring trials reflect our diverse communities."

This collaboration fosters knowledge sharing and strategies for diverse community engagement in clinical trials. AOD, Accelerated Cure Project for Multiple Sclerosis, and the Arab Board for Clinical Research unite for a more inclusive healthcare future.

Reference

Accelerated Cure Project for Multiple Sclerosis and Arab Board for Clinical Research Partner with the Association of Diversity in Clinical Trials. (2023, September 28). Cision PR Newswire.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.